NYSE:EXAM - Examworks Group Stock Price, News, & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Sign in or create an account to add this stock to your watchlist. Get Started Previous Close$35.06Today's Range$35.05 - $35.1752-Week Range$21.98 - $37.26Volume3.56 million shsAverage Volume660,679 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ExamWorks Group, Inc. is a provider of independent medical examinations (IMEs), peer reviews, bill reviews, Medicare compliance, case management and other related services (IME services or the IME industry). The Company conducts its business through four geographic segments, namely, the United States, Canada, the United Kingdom and Australia. The Company provides IME services through its medical panel of credentialed physicians and other medical providers. Its clients include property and casualty insurance carriers, law firms, third-party claim administrators and government agencies that use independent services to confirm the veracity of claims by sick or injured individuals and to facilitate care for workers' compensation, automotive, personal injury liability and disability insurance coverage. The Company also provides a range of services, including Medicare compliance services, bill review services and case management services. Receive EXAM News and Ratings via Email Sign-up to receive the latest news and ratings for EXAM and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry N/A Sub-IndustryHealth Care Services SectorN/A Current SymbolNYSE:EXAM Previous Symbol CUSIP30066A10 CIK1498021 Webhttp://www.examworks.com/ Phone+1-404-9522400Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable Examworks Group (NYSE:EXAM) Frequently Asked Questions What is Examworks Group's stock symbol? Examworks Group trades on the New York Stock Exchange (NYSE) under the ticker symbol "EXAM." How were Examworks Group's earnings last quarter? Examworks Group, Inc. (NYSE:EXAM) announced its earnings results on Tuesday, May, 10th. The business services provider reported $0.08 earnings per share for the quarter, hitting analysts' consensus estimates of $0.08. The business services provider had revenue of $226.50 million for the quarter, compared to the consensus estimate of $217.47 million. Examworks Group's quarterly revenue was up 15.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.05 EPS. View Examworks Group's Earnings History. Has Examworks Group been receiving favorable news coverage? Media headlines about EXAM stock have trended neutral on Friday, InfoTrie reports. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Examworks Group earned a news sentiment score of 0.3 on InfoTrie's scale. They also gave press coverage about the business services provider a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near future. What other stocks do shareholders of Examworks Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Examworks Group investors own include Halozyme Therapeutics (HALO), Ionis Pharmaceuticals (IONS), Nektar Therapeutics (NKTR), Intrexon (XON), Ciena (CIEN), Community Health Systems (CYH), Alnylam Pharmaceuticals (ALNY), Ambarella (AMBA), Anacor Pharmaceuticals (ANAC) and bluebird bio (BLUE). What is Examworks Group's official website? The official website for Examworks Group is http://www.examworks.com/. How can I contact Examworks Group? Examworks Group's mailing address is 3280 Peachtree Rd NE Ste 2625, ATLANTA, GA 30305-2457, United States. The business services provider can be reached via phone at +1-404-9522400. MarketBeat Community Rating for Examworks Group (NYSE EXAM)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 316 (Vote Outperform)Underperform Votes: 228 (Vote Underperform)Total Votes: 544MarketBeat's community ratings are surveys of what our community members think about Examworks Group and other stocks. Vote "Outperform" if you believe EXAM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EXAM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/24/2019 by MarketBeat.com StaffFeatured Article: Why do company’s buyback their stock? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.